Fabio Piscaglia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1563775/publications.pdf

Version: 2024-02-01

272	28,206	9786	5988
papers	citations	73 h-index	160 g-index

278	278	278	20531
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	12.1	57
2	Liver Imaging Reporting and Data System: Review of Pros and Cons. Seminars in Liver Disease, 2022, 42, 104-111.	3.6	2
3	Surveillance for hepatocellular carcinoma with a 3-months interval in â€œextremely high-riskâ€•patients does not further improve survival. Digestive and Liver Disease, 2022, 54, 927-936.	0.9	4
4	Efficacy of a short course of lung ultrasound for primary care physicians in the assessment of COVID-19-positive patients. Family Practice, 2022, 39, 656-661.	1.9	2
5	CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. Radiology, 2022, 302, 326-335.	7.3	32
6	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1185-1198.	3.7	35
7	Pattern of progression of intrahepatic cholangiocarcinoma: Implications for secondâ€line clinical trials. Liver International, 2022, 42, 458-467.	3.9	6
8	Hepatocellular carcinoma in the non-cirrhotic liver. Clinical Hemorheology and Microcirculation, 2022, 80, 423-436.	1.7	10
9	Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). Cancers, 2022, 14, 336.	3.7	5
10	Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3â€“5 cm. Hepatology, 2022, 76, 6-8.	7.3	1
11	Clinical Practice Guidance and Education in Ultrasound: Evidence and experience are two sides of one coin!. Ultraschall in Der Medizin, 2022, 43, 7-11.	1.5	3
12	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.9	3
13	Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. Nutrients, 2022, 14, 1652.	4.1	6
14	Contrastâ€Enhanced Ultrasound (<scp>CEUS</scp>) in the Evaluation of Hemoperitoneum in Patients With Cirrhosis. Journal of Ultrasound in Medicine, 2022, , .	1.7	2
15	Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 2022, 14, 2493.	4.1	7
16	Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. Cancers, 2022, 14, 3421.	3.7	9
17	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-407.	3.9	10
18	Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). Journal of Nephrology, 2021, 34, 77-88.	2.0	8

#	Article	IF	Citations
19	Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver. Magnetic Resonance Imaging, 2021, 75, 9-20.	1.8	9
20	The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-597.	3.9	69
21	Contrast-enhanced ultrasound of the liver in colorectal cancer: AÂuseful tool in the right patient. Journal of Hepatology, 2021, 74, 272-273.	3.7	5
22	Contrast-Enhanced Ultrasound LI-RADS LR-5 in Hepatic Tuberculosis: Case Report and Literature Review of Imaging Features. Gastroenterology Insights, 2021, 12, 1-9.	1.2	13
23	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clinical and Translational Gastroenterology, 2021, 12, e00286.	2.5	15
24	Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110169.	3.2	74
25	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	7.7	31
26	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	3.9	45
27	Retrospective analysis of safety of ultrasound-guided percutaneous liver biopsy in the 21st century. European Journal of Gastroenterology and Hepatology, 2021, 33, e355-e362.	1.6	4
28	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. International Journal of Biological Markers, 2021, 36, 54-61.	1.8	8
29	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	3.4	18
30	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells, 2021, 10, 521.	4.1	13
31	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers, 2021, 13, 1673.	3.7	21
32	Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoproteinâ€‰â‰¥â€‰400Âng/mL: A Matching-Adjusted Indirect Comparison. Advances in Therapy, 2021, 38, 2472-2490.	3.9	9
33	Tocilizumab: From Rheumatic Diseases to COVID-19. Current Pharmaceutical Design, 2021, 27, 1597-1607.	1.9	4
34	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 369-385.	3.7	12
35	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology, 2021, 56, 570-580.	5.1	6
36	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 477-492.	3.7	15

#	Article	IF	Citations
37	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. Hepatology Research, 2021, 51, 796-802.	3.4	4
38	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. Liver Cancer, 2021, 10, 1-2.	7.7	1
39	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. Clinical Cancer Research, 2021, 27, 4848-4858.	7.0	39
40	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	3.9	18
41	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201.	2.4	13
42	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 741-757.	3.7	29
43	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound in Medicine and Biology, 2021, 47, 2803-2820.	1.5	63
44	Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for COVID-19 Pandemic. Diagnostics, 2021, 11, 82.	2.6	5
45	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. Journal of Personalized Medicine, 2021, 11, 1041.	2.5	48
46	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	2.8	4
47	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Management and Research, 2021, Volume 13, 9379-9389.	1.9	31
48	Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. Cancers, 2021, 13, 6376.	3.7	13
49	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. Hepatology, 2020, 71, 658-669.	7.3	95
50	Anticoagulation in Cirrhotic Portal Vein Thrombosis: No Harm, but Survival Benefit Still Unclear. American Journal of Gastroenterology, 2020, 115, 145-146.	0.4	1
51	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	3.6	12
52	The expanding potential of functional liver imaging: From research tools to clinical practice in oncology and internal medicine. European Journal of Internal Medicine, 2020, 79, 23-24.	2.2	1
53	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver â€“ Update 2020 â€“ WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall in Der Medizin, 2020, 41, 562-585.	1.5	130
54	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liverâ€“Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound in Medicine and Biology, 2020, 46, 2579-2604.	1.5	210

#	Article	IF	Citations
55	Artificial Intelligence: What Is It and How Can It Expand theÂUltrasound Potential in the Future?. Ultraschall in Der Medizin, 2020, 41, 356-360.	1.5	8
56	Contrast-Enhanced Ultrasound: Development of Syllabus for Core Theoretical and Practical Competencies. Ultrasound in Medicine and Biology, 2020, 46, 2287-2292.	1.5	8
57	SIUMB recommendations for focal pancreatic lesions. Journal of Ultrasound, 2020, 23, 599-606.	1.3	6
58	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. Cancers, 2020, 12, 2674.	3.7	13
59	Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. Liver Cancer, 2020, 9, 744-755.	7.7	15
60	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	2.5	29
61	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€analysis. Liver International, 2020, 40, 1435-1446.	3.9	35
62	Ablation for hepatocellular carcinoma: beyond the standard indications. Medical Oncology, 2020, 37, 23.	2.5	7
63	MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research, 2020, 80, 1720-1734.	0.9	47
64	Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?. Journal of Hepatology, 2020, 72, 607-609.	3.7	4
65	Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US. Radiology, 2020, 295, 245-247.	7.3	12
66	Benefits, Open questions and Challenges of the use of Ultrasound inÂthe COVID-19 pandemic era. The views of a panel of worldwide international experts. Ultraschall in Der Medizin, 2020, 41, 228-236.	1.5	46
67	Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers, 2020, 12, 794.	3.7	32
68	Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. Journal of Clinical Oncology, 2020, 38, 478-478.	1.6	93
69	Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 3909-3914.	1.9	7
70	The Perceived Ability of Gastroenterologists, Hepatologists and Surgeons Can Bias Medical Decision Making. International Journal of Environmental Research and Public Health, 2020, 17, 1058.	2.6	10
71	An Uncommon Focal Liver Lesion: Intrahepatic Splenosis. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 257-262.	0.9	6
72	Reader agreement and accuracy of ultrasound features for hepatic steatosis. Abdominal Radiology, 2019, 44, 54-64.	2.1	16

#	Article	IF	Citations
73	Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer, 2019, 19, 795.	2.6	48
74	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2019, 121, 218-221.	6.4	22
75	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. Journal of Hepatology, 2019, 71, 1175-1183.	3.7	64
76	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 34-42.	1.6	58
77	Different techniques for ultrasound liver elastography. Journal of Hepatology, 2019, 70, 545-547.	3.7	13
78	Contrast-enhanced harmonic endoscopic ultrasound-guided ethanol injection for a small hepatocellular carcinoma. Endoscopy, 2019, 51, E317-E318.	1.8	8
79	Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Digestive and Liver Disease, 2019, 51, 1067-1073.	0.9	25
80	Ultrasound in the Assessment of Tumor Response in the Age of Targeted and Immuno-Oncology Therapies. Back to the Future. Ultraschall in Der Medizin, 2019, 40, 129-131.	1.5	0
81	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Scientific Reports, 2019, 9, 3781.	3.3	18
82	What Ultrasound Operators Must Be Well Aware of in a World With Raising Burden of Non Alcoholic Fatty Liver Disease?. Ultraschall in Der Medizin, 2019, 40, 7-10.	1.5	3
83	MicroRNAs in Animal Models of HCC. Cancers, 2019, 11, 1906.	3.7	25
84	Reply to Anticoagulation for Portal Vein Thrombosis in Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1001-1002.	0.4	2
85	Imaging of combined hepatocellularâ€cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 69-77.	3.8	31
86	European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Policy Document Development Strategy â€“ Clinical Practice Guidelines, Position Statements and Technological Reviews. Ultrasound International Open, 2019, 05, E2-E10.	0.6	24
87	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).. Journal of Clinical Oncology, 2019, 37, 317-317.	1.6	26
88	Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs. Translational Cancer Research, 2019, 8, S223-S232.	1.0	2
89	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall in Der Medizin, 2018, 39, e2-e44.	1.5	627
90	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Short Version). Ultraschall in Der Medizin, 2018, 39, 154-180.	1.5	196

#	Article	IF	Citations
91	Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer, 2018, 7, 104-119.	7.7	95
92	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	3.7	6,153
93	Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. European Radiology, 2018, 28, 3611-3620.	4.5	55
94	New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut, 2018, 67, 1674-1682.	12.1	114
95	How to perform Contrast-Enhanced Ultrasound (CEUS). Ultrasound International Open, 2018, 04, E2-E15.	0.6	222
96	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. Bone Marrow Transplantation, 2018, 53, 591-599.	2.4	8
97	Ultrasound Elastography: General and Technical Overview. , 2018, , 83-94.		0
98	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, The, 2018, 391, 1163-1173.	13.7	3,542
99	CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdominal Radiology, 2018, 43, 127-142.	2.1	147
100	A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology, 2018, 67, 467-469.	7.3	13
101	Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdominal Radiology, 2018, 43, 861-879.	2.1	85
102	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	7.3	93
103	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. Journal of Hepatology, 2018, 68, 485-492.	3.7	195
104	Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. Liver International, 2018, 38, 278-284.	3.9	10
105	DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. The Lancet Gastroenterology and Hepatology, 2018, 3, 736-738.	8.1	6
106	Widen NomoGram for multinomial logistic regression: an application to staging liver fibrosis in chronic hepatitis C patients. Statistical Methods in Medical Research, 2017, 26, 823-838.	1.5	4
107	A metaâ€analysis of single <scp>HCV</scp>â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp>â€related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	3.9	70
108	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.9	254

#	Article	IF	Citations
109	Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard andÂPrecise Terminology for Describing Enhancement Criteria. Ultraschall in Der Medizin, 2017, 38, 9-11.	1.5	16
110	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall in Der Medizin, 2017, 38, e16-e47.	1.5	659
111	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall in Der Medizin, 2017, 38, 377-394.	1.5	93
112	American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay. Ultraschall in Der Medizin, 2017, 38, 320-324.	1.5	84
113	Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADSÂ®): the official version by the American College of Radiology (ACR). Ultraschall in Der Medizin, 2017, 38, 85-86.	1.5	110
114	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. Digestive and Liver Disease, 2017, 49, 802-808.	0.9	51
115	Bidimensional shear wave ultrasound elastography with supersonic imaging to predict presence of oesophageal varices in cirrhosis. Liver International, 2017, 37, 1405-1405.	3.9	18
116	Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness. Journal of Ultrasound, 2017, 20, 213-225.	1.3	23
117	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer, 2017, 6, 337-348.	7.7	18
118	Antithrombotic treatment with directâ€acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	3.9	178
119	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	3.7	70
120	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver International, 2017, 37, 423-433.	3.9	46
121	Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A metaâ€analysis of randomized trials. United European Gastroenterology Journal, 2017, 5, 511-518.	3.8	67
122	A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, 1134.	4.1	27
123	Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 â€“ a review of important differences compared to the CT/MRI system. Clinical and Molecular Hepatology, 2017, 23, 280-289.	8.9	96
124	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2017, 35, 4001-4001.	1.6	65
125	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	7.3	467
126	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clinical and Experimental Immunology, 2016, 185, 61-71.	2.6	75

#	Article	IF	Citations
127	Natural history of nonalcoholic steatohepatitisâ€“associated hepatocellular carcinoma. Clinical Liver Disease, 2016, 8, 105-107.	2.1	2
128	Ongoing challenges in the diagnosis of hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2016, 10, 451-463.	3.0	5
129	Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVueÂ®. Liver Cancer, 2016, 5, 55-66.	7.7	20
130	EUS Needle Identification Comparison and Evaluation study (withÂvideos). Gastrointestinal Endoscopy, 2016, 84, 424-433.e2.	1.0	23
131	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.9	57
132	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. American Journal of Gastroenterology, 2016, 111, 70-77.	0.4	59
133	Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. Journal of Hepatology, 2016, 64, 79-86.	3.7	83
134	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. Internal and Emergency Medicine, 2016, 11, 19-30.	2.0	11
135	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	8.4	113
136	Utilityâ€based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alphaâ€fetoprotein model as a survival predictor. Liver Transplantation, 2015, 21, 1250-1258.	2.4	10
137	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediateâ€“advanced hepatocellular carcinoma. Future Oncology, 2015, 11, 3133-3142.	2.4	20
138	Hepatorenal syndrome: Update on diagnosis and treatment. World Journal of Nephrology, 2015, 4, 511.	2.0	37
139	When to perform hepatic resection for intermediateâ€stage hepatocellular carcinoma. Hepatology, 2015, 61, 905-914.	7.3	69
140	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Digestive Diseases, 2015, 33, 735-744.	1.9	19
141	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. Journal of Hepatology, 2015, 62, 617-624.	3.7	184
142	Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. Molecular Imaging and Biology, 2015, 17, 29-37.	2.6	48
143	Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontiÃ¨res meeting 2013. European Radiology, 2015, 25, 3438-3454.	4.5	247
144	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Digestive and Liver Disease, 2015, 47, 518-522.	0.9	63

#	Article	IF	Citations
145	Indications for Liver Transplantation. , 2015, , 97-125.		1
146	Single hepatocellular carcinoma smaller than 2 cm: are ethanol injection and radiofrequency ablation equally effective?. Anticancer Research, 2015, 35, 325-32.	1.1	21
147	The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series. Digestive Diseases, 2014, 32, 711-716.	1.9	47
148	Assessment of long-term prognosis at detection of early hepatocellular carcinoma remains unsolved. Journal of Hepatology, 2014, 61, 1438.	3.7	0
149	Extracorporeal Detoxification for Hepatic Failure Using Molecular Adsorbent Recirculating System: Depurative Efficiency and Clinical Results in a Longâ€Term Followâ€Up. Artificial Organs, 2014, 38, 125-134.	1.9	37
150	An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Digestive and Liver Disease, 2014, 46, 257-263.	0.9	43
151	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 995-1001.	3.7	61
152	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	5.1	109
153	The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives. European Journal of Radiology, 2014, 83, 450-455.	2.6	57
154	TACE performed in patients with a single nodule of Hepatocellular Carcinoma. BMC Cancer, 2014, 14, 601.	2.6	36
155	Imaging of Liver Tumors in Patients with Chronic Liver Disease. Current Radiology Reports, 2014, 2, 1.	1.4	3
156	Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. BMC Cancer, 2014, 14, 403.	2.6	7
157	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group. Digestive and Liver Disease, 2014, 46, 549-555.	0.9	57
158	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver â€“ Update 2012. Ultrasound in Medicine and Biology, 2013, 39, 187-210.	1.5	652
159	Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma â©½3cm. Results of a multicenter Italian survey. Journal of Hepatology, 2013, 59, 89-97.	3.7	241
160	Field practice studies on sorafenib: Lessons in systemic treatment of hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 367-368.	0.9	3
161	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. Journal of Hepatology, 2013, 58, 1188-1193.	3.7	110
162	The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. Digestive and Liver Disease, 2013, 45, 762-768.	0.9	76

#	Article	IF	Citations
163	Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: Some enthusiasm with a word of caution. Journal of Hepatology, 2013, 59, 924-925.	3.7	8
164	Treatment of hepatocellular carcinoma in Child-Pugh B patients. Digestive and Liver Disease, 2013, 45, 852-858.	0.9	32
165	Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 300-307.	3.7	323
166	Hepatocellular Carcinoma Responding to Superselective Transarterial Chemoembolization: An Issue of Nodule Dimension?. Journal of Vascular and Interventional Radiology, 2013, 24, 509-517.	0.5	95
167	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 712-723.	0.9	155
168	Reply to: â€œNon-invasive diagnosis of small nodules in cirrhosisâ€• Journal of Hepatology, 2013, 59, 1361-1362.	3.7	0
169	Impact of gadoxetic acid (Gdâ€‹scp›EOB‹/scp›â€‹scp›DTPA‹/scp›)â€enhanced magnetic resonance on the nonâ€invasive diagnosis of small hepatocellular carcinoma: a prospective study. Alimentary Pharmacology and Therapeutics, 2013, 37, 355-363.	3.7	98
170	Long-term effectiveness of Radiofrequency Ablation for solitary small Hepatocellular Carcinoma: A retrospective analysis of 363 patients. Digestive and Liver Disease, 2013, 45, 336-341.	0.9	44
171	Safety of Ultrasound Contrast Agents in Patients With Known or Suspected Cardiac Shunts. American Journal of Cardiology, 2013, 112, 1039-1045.	1.6	53
172	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. Seminars in Liver Disease, 2013, 32, 348-359.	3.6	508
173	Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases. Hepatitis Monthly, 2013, 13, e11721.	0.2	29
174	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2013, 25, 1385-1395.	1.6	3
175	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver International, 2013, 33, 771-779.	3.9	91
176	Yttrium 90 radioembolization: The horizon is changing for patients with intermediate and advanced hepatocellular carcinoma. Hepatology, 2013, 57, 1694-1696.	7.3	2
177	Systematic review of surgical resection‹i›vs‹/i›radiofrequency ablation for hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 4106.	3.3	77
178	Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, e15149-e15149.	1.6	0
179	Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients. Clinical Cancer Research, 2012, 18, 4397-4405.	7.0	87
180	Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances. Current Pharmaceutical Design, 2012, 18, 2236-2252.	1.9	45

#	Article	IF	Citations
181	Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): Comments on AASLD guidelines. Journal of Hepatology, 2012, 57, 930-932.	3.7	80
182	Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters. European Journal of Radiology, 2012, 81, 709-713.	2.6	21
183	Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. European Journal of Radiology, 2012, 81, 4112-4118.	2.6	156
184	Response rate and clinical outcome of HCC after first and repeated cTACE performed â€œon demandâ€: Journal of Hepatology, 2012, 57, 1258-1267.	3.7	126
185	Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma. Liver Cancer, 2012, 1, 190-200.	7.7	78
186	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 1015-1021.	0.9	10
187	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews, 2011, 37, 212-220.	7.7	460
188	Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transplantation, 2011, 17, 1344-1354.	2.4	91
189	Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology, 2011, 53, 1580-1589.	7.3	229
190	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology, 2011, 54, 2055-2063.	7.3	321
191	Role of Contrast-Enhanced Ultrasonography in Primary Hepatic Lymphoma. Journal of Ultrasound in Medicine, 2010, 29, 1353-1356.	1.7	35
192	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transplantation, 2010, 16, 658-667.	2.4	93
193	Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation. Liver Transplantation, 2010, 16, 1006-1007.	2.4	21
194	Characterization of Focal Liver Lesions with Contrast-Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2010, 36, 531-550.	1.5	102
195	Contrast Enhanced Imaging Pattern of Central Scar in Focal Nodular Hyperplasia. Ultrasound in Medicine and Biology, 2010, 36, 2146-2147.	1.5	1
196	Contrast Enhanced Ultrasonography for the Evaluation of Coil Embolization of Splenic Artery Aneurysm. Circulation, 2010, 122, e451-4.	1.6	6
197	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, 729-734.	0.9	12
198	â€œSurvival benefitâ€: The final destination, with still a long way to go. Digestive and Liver Disease, 2010, 42, 608-610.	0.9	2

#	Article	IF	Citations
199	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. Digestive and Liver Disease, 2010, 42, S258-S263.	0.9	51
200	The Impact of Vascular and Nonvascular Findings on the Noninvasive Diagnosis of Small Hepatocellular Carcinoma Based on the EASL and AASLD Criteria. American Journal of Gastroenterology, 2010, 105, 599-609.	0.4	185
201	Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: A pilot study. Journal of Hepatology, 2010, 52, 880-888.	3.7	168
202	Down-staging of hepatocellular carcinoma prior to liver transplantation: The power of selection. Hepatology, 2009, 49, 1056-1056.	7.3	1
203	Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transplantation, 2009, 15, 782-789.	2.4	74
204	Expression of ECM proteins fibulin-1 and -2 in acute and chronic liver disease and in cultured rat liver cells. Cell and Tissue Research, 2009, 337, 449-462.	2.9	27
205	Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy?. Clinical Transplantation, 2009, 23, 519-524.	1.6	18
206	Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population. Annals of Surgical Oncology, 2009, 16, 413-422.	1.5	178
207	Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: Usefulness of transient elastography. Digestive and Liver Disease, 2009, 41, 217-225.	0.9	71
208	A benign tumour of the liver mimicking malignant liver disease â€“ cholangiocellular adenoma. Scandinavian Journal of Gastroenterology, 2009, 44, 633-636.	1.5	36
209	Down-Staging of Hepatocellular Carcinoma Before Liver Transplantation: Should We Change Our Clinical Practice?. Annals of Surgery, 2009, 250, 348.	4.2	2
210	Onset of bronchiolitis obliterans organizing pneumonia in a liver transplant recipient under peg-interferon and ribavirin treatment. Internal and Emergency Medicine, 2008, 3, 77-80.	2.0	4
211	Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria. American Journal of Transplantation, 2008, 8, 2547-2557.	4.7	341
212	Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2008, 48, 848-857.	3.7	113
213	Malignancies in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2008, 20, 1-4.	1.6	20
214	Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. Gut, 2007, 56, 253-258.	12.1	70
215	High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?. Gut, 2007, 56, 237-242.	12.1	108
216	Characterization of liver lesions by real-time contrast-enhanced ultrasonography. European Journal of Gastroenterology and Hepatology, 2007, 19, 3-14.	1.6	68

#	Article	IF	Citations
217	New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Digestive and Liver Disease, 2007, 39, 187-195.	0.9	74
218	A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transplantation, 2007, 13, 857-866.	2.4	45
219	Selecting patients with hepatocellular carcinoma for transplantation. Liver Transplantation, 2007, 13, 1203-1203.	2.4	3
220	Outcomes from a program of home care attendance in very frail elderly subjects. Archives of Gerontology and Geriatrics, 2007, 44, 95-103.	3.0	8
221	Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer, 2007, 7, 171.	2.6	64
222	Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research, 2007, 37, S178-92.	3.4	18
223	Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. Clinical Gastroenterology and Hepatology, 2006, 4, 1395-1402.	4.4	10
224	Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. European Journal of Gastroenterology and Hepatology, 2006, 18, 1255-1261.	1.6	48
225	The safety of SonovueÂ® in abdominal applications: Retrospective analysis of 23188 investigations. Ultrasound in Medicine and Biology, 2006, 32, 1369-1375.	1.5	654
226	Detection of HCV antigens in liver graft: Relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transplantation, 2006, 12, 1673-1681.	2.4	19
227	Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. Hepatology, 2005, 42, 27-34.	7.3	410
228	Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression. Liver Transplantation, 2005, 11, 497-503.	2.4	191
229	Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transplantation, 2005, 11, 1117-1126.	2.4	204
230	Clinico-Pathological Classification. , 2005, , 75-83.		0
231	Caution in the use of boldo in herbal laxatives: A case of hepatotoxicity. Scandinavian Journal of Gastroenterology, 2005, 40, 236-239.	1.5	18
232	Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. Journal of Hepatology, 2005, 43, 310-316.	3.7	44
233	Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut, 2004, 53, 1020-1023.	12.1	190
234	Use of perfusional angiosonography in liver transplantation and conservatve management of post-transplant intra-hepatie pseudo-aneurysm. Transplant International, 2004, 17, 634-638.	1.6	0

#	Article	IF	Citations
235	Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. Transplant International, 2004, 17, 634-638.	1.6	2
236	Hepatic artery thrombosis and graft ischemia in the presence of preserved arterial inflow: Not a contradiction but a real possibility. Liver Transplantation, 2004, 10, 710-711.	2.4	6
237	Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. Journal of Hepatology, 2004, 41, 421-426.	3.7	122
238	Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology, 2003, 34, 608-608.	7.3	27
239	Liver metastases from rectal carcinoma: Disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. Journal of Clinical Ultrasound, 2003, 31, 387-391.	0.8	15
240	Portal pressure and Doppler. Ultrasound in Medicine and Biology, 2003, 29, 495-496.	1.5	1
241	Effect of LevovistÂ® on splanchnic hemodynamics in cirrhotic patients. Ultrasound in Medicine and Biology, 2003, 29, 643-648.	1.5	4
242	In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. Journal of Hepatology, 2003, 39, 997-1003.	3.7	40
243	Cirrhosis does not shift the circadian phase of plasma fibrinolysis. American Journal of Gastroenterology, 2002, 97, 1512-1517.	0.4	7
244	Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the differentiation of HSC from other liver myofibroblasts. Journal of Hepatology, 2002, 36, 607-613.	3.7	82
245	Vascularity of liver tumours and recent advances in Doppler ultrasound. Journal of Hepatology, 2001, 34, 474-482.	3.7	42
246	Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. Ultrasound in Medicine and Biology, 2001, 27, 893-899.	1.5	66
247	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 2001, 48, 251-259.	12.1	567
248	Liver cirrhosis, ascites, and hyperfibrinolysis. American Journal of Gastroenterology, 2001, 96, 3222-3222.	0.4	10
249	Influence of Esophageal Varices and Spontaneous Portal-Systemic Shunts on Postprandial Splanchnic Hemodynamics. American Journal of Gastroenterology, 2001, 96, 550-556.	0.4	17
250	Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology, 2001, 34, 608-608.	7.3	41
251	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology, 2000, 31, 349-357.	7.3	37
252	Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate. Digestive Diseases and Sciences, 2000, 45, 306-311.	2.3	5

#	Article	IF	Citations
253	Assessment of Vascular Patterns of Small Liver Mass Lesions: Value and Limitation of The Different Doppler Ultrasound Modalities. American Journal of Gastroenterology, 2000, 95, 3537-3546.	0.4	45
254	Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Ultrasound in Medicine and Biology, 1999, 25, 923-932.	1.5	9
255	Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair. Histochemistry and Cell Biology, 1999, 112, 387-401.	1.7	164
256	Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Biochemical Pharmacology, 1999, 58, 157-165.	4.4	46
257	Splanchnic arterial doppler parameters in portal hypertension. Hepatology, 1999, 29, 1610-1610.	7.3	1
258	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology, 1999, 30, 58-64.	7.3	141
259	Intrahepatic artery pseudoaneurysm: A possible complication of blind thoracentesis. , 1999, 27, 151-155.		6
260	Hemodynamics in focal nodular hyperplasia. Journal of Hepatology, 1999, 31, 576.	3.7	21
261	Nodule in Nodule: Malignant Transformation of a Macroregenerative Nodule in Cirrhosis Revealed by Duplex-Doppler. Journal of Hepatology, 1999, 30, 955.	3.7	4
262	Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology, 1999, 117, 1205-1221.	1.3	316
263	Duplex Doppler findings in splenic arteriovenous fistula. , 1998, 26, 103-105.		10
264	Diagnosis of Cirrhosis and Portal Hypertension. American Journal of Gastroenterology, 1998, 93, 1598-1599.	0.4	3
265	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. American Journal of Gastroenterology, 1998, 93, 1925-1930.	0.4	32
266	Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. European Journal of Gastroenterology and Hepatology, 1997, 9, 799-804.	1.6	31
267	What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. Journal of Hepatology, 1997, 27, 979-985.	3.7	256
268	High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. Digestive Diseases and Sciences, 1997, 42, 2024-2030.	2.3	77
269	A case of extracranial vertebral artery dissection with spontaneous recovery. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 1997, 6, 197-201.	1.3	2
270	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. Ultrasound in Medicine and Biology, 1997, 23, 675-682.	1.5	54

#	Article	IF	Citations
271	E<scp>ditorial</scp>: Cigarette smoking, abdominal blood flow and abdominal diseases. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 995-996.	2.8	0
272	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 1115-1120.	2.8	17